Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically proven locally advanced or metastatic non-small cell lung cancer that is not amenable to curative surgery or radiotherapy No known CNS metastases No concurrent cord compression or superior vena cava syndrome requiring immediate radiotherapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 40-70% Life expectancy: At least 4 weeks Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10.0 g/dL Hepatic: Bilirubin no greater than 3 times normal ALT and AST no greater than 3 times normal (5 times normal if liver metastasis present) Renal: Creatinine no greater than 1.5 times normal Other: Not pregnant or nursing Fertile patients must use effective contraception during and for at least 3 months after study No active infection No other concurrent serious, systemic disorder that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy No other concurrent systemic chemotherapy Endocrine therapy: Concurrent steroids allowed Radiotherapy: See Disease Characteristics Concurrent palliative radiotherapy allowed No concurrent curative radiotherapy Surgery: See Disease Characteristics Concurrent palliative surgery allowed
Sites / Locations
- Christie Hospital N.H.S. Trust